FerGene
  • About
  • Leadership
  • Culture
  • Careers
  • Media
  • Collaboration
  • THEBLADDERMATTERS.COM
Select Page

Site Map

  • About
  • Careers
  • Collaboration
  • Culture
  • Home
  • Leadership
  • Legal Notice
  • Media
  • Privacy Policy
  • Sitemap
  • FerGene announces Landmark Phase 3 study published in Lancet Oncology
  • FerGene announces pivotal Phase 3 study of nadofaragene firadenovec met its primary endpoint with more than half of patients with high-grade non-muscle invasive bladder cancer (CIS ± Ta/T1) achieving a complete response at three months
  • FerGene Appoints David Meek Chief Executive Office
  • FerGene Appoints Top Biotech Leaders to Executive Team
  • FerGene Provides Update on BLA for Nadofaragene Firadenovec
  • FerGene to present bladder cancer data at 2020 ASCO Genitourinary Cancers Symposium
  • Ferring and Blackstone Life Sciences invest over $570 million USD in novel investigational gene therapy for bladder cancer patients
  • New Analysis of Phase 3 study presented at SUO 2020

FerGene

245 Main Street

Cambridge, MA 02142

Tel: (617) 865-5780
communications@FerGene.com
linkedin-logotwitter-logo
Privacy PolicyLegal NoticeSitemap
FerGene: A Blackstone-Ferring Collaboration

Information on this site is intended for US audiences only.

© 2020 FerGene, Inc. 2020/06 US-FRG-2000004

You are now leaving
www.FerGene.com

Stay here arrow
Leave site arrow

You are now leaving
www.FerGene.com

Stay here arrow
Leave site arrow